February 1, 2018 / 9:20 PM / 24 days ago

BRIEF-FDA Granted Alnylam's Request For Priority Review

Feb 1 (Reuters) - Alnylam Pharmaceuticals Inc:

* ALNYLAM ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRIORITY REVIEW STATUS FOR PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

* ALNYLAM PHARMACEUTICALS INC - FDA ALSO GRANTED COMPANY‘S REQUEST FOR PRIORITY REVIEW AND HAS SET AN ACTION DATE OF AUGUST 11, 2018

* ALNYLAM PHARMACEUTICALS INC - ‍AT THIS TIME, FDA IS NOT PLANNING TO HOLD AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below